Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 44 clinical trials
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients

The purpose of this study is to test any good and bad effects of the study drug called brentuximab vedotin at a lower dose than is FDA-approved.

sezary syndrome
cancer therapy
immunomodulator
mycosis fungoides and sezary syndrome
cancer
  • 115 views
  • 05 Mar, 2022
  • 8 locations
Brentuximab Vedotin Plus DHAP in Relapsed or Refractory Hodgkin's Lymphoma

< STUDY DESIGN > This study is a multi-center phase II trial in patients with relapsed or refractory Hodgkin's lymphoma after first-line treatment. < Treatment Schedule > Induction phase Patients who sign the informed consent form (ICF) receive BV-DHAP induction therapy within 21 days. Tumor response is evaluated following 2 …

  • 0 views
  • 24 Mar, 2022
Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma

This phase II trial studies how well brentuximab vedotin and nivolumab work in treating patients with stage I-II classic Hodgkin lymphoma. Brentuximab vedotin is a monoclonal antibody

nivolumab
nodular sclerosis
avid
tumor cells
lymphoma
  • 3 views
  • 15 Feb, 2022
  • 11 locations
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

This phase II trial investigates how well brentuximab vedotin and bendamustine work in treating patients with follicular lymphoma that has come back (relapsed) or does not respond to treatment

  • 0 views
  • 27 Dec, 2021
  • 1 location
Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma

This phase II clinical trial studies how well giving brentuximab vedotin together with pembrolizumab in treating patients with peripheral T-cell lymphoma (PTCL) that has come back (recurrent

  • 0 views
  • 05 Jul, 2022
  • 1 location
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery

This phase II trial studies how well brentuximab vedotin works in treating patients with CD30 positive (+) malignant mesothelioma that cannot be removed by surgery. Monoclonal antibodies, such

metastasis
malignant mesothelioma
measurable disease
unresectable malignant mesothelioma
neutrophil count
  • 112 views
  • 24 Mar, 2022
  • 1 location
A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma

This is a Phase I Trial to assess the feasibility of Romidepsin combined with Brentuximab Vedotin for patients requiring Systemic Therapy for Cutaneous T-cell Lymphoma.

sezary syndrome
neutrophil count
mycosis fungoides
psoralen
lymphoma
  • 2 views
  • 04 Oct, 2022
  • 1 location
Brentuximab Vedotin as Alternative to the Autologous Stem Cell Transplantation in Relapsed and Refractory Classical Hodgkin's Lymphoma (BASALT) (BASALT)

This study evaluate possibility of brentuximab vedotin, administered after first treatment failure (no response or relapse after I line therapy) of Hodgkin's lymphoma, to induce durable response

platelet count
brentuximab
measurable disease
classical hodgkin lymphoma
cell transplantation
  • 3 views
  • 04 Feb, 2022
  • 2 locations
A Phase I Study With an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients With Relapsed/Refractory Hodgkin Lymphoma

This phase I/II trial studies the side effects and best dose of ipilimumab and nivolumab when given together with brentuximab vedotin, and how well they work in treating patients with Hodgkin

  • 158 views
  • 24 Oct, 2022
  • 254 locations
A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)

treatment. This clinical trial uses a drug called Brentuximab Vedotin. The Food and Drug Administration (FDA) has approved Brentuximab Vedotin for sale in the United States for certain diseases

peripheral t-cell lymphoma
t-cell leukemia
avid
enteropathy
lymphoma
  • 25 views
  • 04 Oct, 2022
  • 2 locations